Imaging and angiogenesis: DCE-US (dynamic contrast enhanced- ultrasonography);Imagerie et angiogenèse: La DCE-US (dynamic contrast enhanced-ultrasonography)

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Lassau, Nathalie ^a   Roche, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic molecules; Contrast agents; Doppler ultrasonography; Dynamic contrast enhanced ultrasonography

Indexed keywords

CONTRAST MEDIUM;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; COMPUTER PROGRAM; DIAGNOSTIC IMAGING; ECHOGRAPHY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; REVIEW; VASCULARIZATION;

ANIMALS; CONTRAST MEDIA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ULTRASONOGRAPHY;

EID: 34548615482     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0416     Document Type: Review

References (37)

1. Rehman S, Jayson G. Molecular imaging of antiangiogenic agents. Oncologist 2005 ; 10 : 92-103.
2. World Health Organisation. WHO handbook for reporting results of cancer treatment. Geneva. 1979.
3. Therasse P, Arbuck SG, Eisenhaur EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 ; 92 : 205-16.
4. Schwartz L. Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th scientific assembly and annual meeting, Chicago. Proc Radiology 2004 : 115.
5. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using Recist, at least in gastrointestinal stromal tumors. J Clin Oncol 2007 ; 25 : 1760-4.
6. Cosgrove D. Angiogenesis imaging : ultrasound. Br J Radiol 2003 ; 76 : 43-9.
7. Lassau N, Chawi I, Rouffiac V, Bidault S, Escudier B, Leclere J. Interest of colour Doppler ultrasonography to evaluate a new anti-angigenic treatment with thalidomide in metastatic renal call carcinoma. Bull Cancer 2004 ; 91 : 629-35.
8. Lassau N, Paturel-Asselin C, Guinebretière JM, et al. New haemodynamic approach to angiogenesis : colour and pulsed Doppler ultrasonography. Invest Radiol 1999 ; 34 : 194-8.
9. Asselin C, Lassau N, Guinebretiere JM et al. The in vivo murineiterleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of turnout blood vessel formation monitored by Doppler unltrasonography. Gene Therapy 199 ; 4 : 606-15.
10. Kaliski A, Maggiorella L, Mathé D, Rouffiac V, Opolon P, Peronneau P, et al. Angiogenic and tumor growth inhibition by an MMP-inhibitor targeting radio-induced MMP-2 and VEGF. Mol Cancer Ther 2005 ; 4 : 1717-28.
11. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002 ; 13 : 1029-35.
12. Faivre S, Delbaldo C, Vera K, Lozahic S, Lassau N, Bello C, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 ; 24 : 25-35.
13. Hochedez P, Lassau N, Bonvalot S, Bidault S, Leclere J, Avril MF. Treatment of local recurrent melanomas by isolated limb perfusion : value of Doppler ultrasonography. J Radiol 2003 ; 84 : 597-603.
14. Lassau N, Koscielny S, Opolon P, et al. Evaluation of contrast-enhanced colour Doppler ultrasound for the quantification of angiogenenis in vivo. Invest Radiol 2001 ; 36 : 50-5.
15. Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas : prospective study of 49 cases. Ann Oncol 2005 ; 16 : 1054-60.
16. Eggermont AM. Evolving imaging technology : contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 2005 ; 16 : 995-6.
17. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology : interest of ultrasonographic contrast agents. J Radiol 2004 ; 85 : 704-12.
18. Lassau N, Leclère J, Peronneau P. In : Lencioni R, ed. Follow-up of oncology patients undergoing chemotherapy. Enhancing the role of ultrasound with contrast agents. Milan : Springer, 2006.
19. Conolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003 ; 90 : 1178-86.
20. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors : dependence on anatomic site. Am J Surg Pathol 1999 ; 23 : 82-7.
21. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 ; 344 : 1052-6.
22. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours : a phase I study. Lancet 2001 ; 358 : 1421-3.
23. Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors : a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002 ; 38(Suppl 5) : S83-S87.
24. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GIST) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002 ; 179 : 1059-62.
25. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos A, et al. Consensus meeeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005 ; 16 : 993.
26. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, et al. Recommendations for the management of GIST patients. Bull Cancer 2005 ; 92 : 907-18.
27. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier, et al. Gastro-intestinal stromal tumours treated with Imatinib : Monitoring response with contrast enhanced ultrasound. Am J Roentgenol 2006 ; 187 : 1267-73.
28. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Tursz T, et al. Doppler-ultrasonogaphy with perfusion software and contrast medium injection as a tool for early evaluation of gastro-intestinal stromal tumors (GIST). ASCO Annual Meeting Proceedings. J Clin Oncol 2005 ; 23 : 206.
29. Lamuraglia M, Escudier B, Chami L, Schwarrz B, Leclere J, Roche A, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib : pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006 ; 42 : 2472-9.
30. Robert C, Lassau N, Angevin E, Soria J, Chami L, Zarafana E, et al. Phase I trial of sorafenib (BAy-43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. ECCO13, European Cancer Conference 2005. Eur J Cancer 2005 ; 3(suppl.) : 254.
31. Claassen L, Seidel G, Algermissen C. Quantification of flow rates using harmonic grey-scale imaging and an ultrasound contrast agent : an in vitro and in vivo study. Ultrasound Med Biol 2001 ; 27 : 83-8.
32. Yeh C, Yang M, Li P. Contrast-specific ultrasonic flow measurements based on both input and outpout time intensities. Ultrasound Med Biol 2003 ; 29 : 671-8.
33. Lavisse S, Lejeune P, Bissery MC, Elie N, Rouffiac N. Brule A et al. Early evaluation of the vascular targeting agent AVE 8062A in melanoma tumor-beating mice using dynamic contrast enhanced-ultrasonography (DCE-US). American Association for Cancer Research, Washington DC, 2006 ; 47 (abstr 987).
34. Armand JP, Loriot Y, Ropert S, Catteau A, Soria JC, Lassau N. Perfusion assessment of tumors by doppler ultrasonography, a tool for early evaluation of targeted antiangiogenic compounds. Ann Oncol 2006 ; 17 (Supp 3) : iii21.
35. Buonaccorsi GA, Roberts C, Cheung S, Watson Y, Davies K, Jackson A, et al. Tracer kinetic medol-dtiven registration for dynamic contrast enhanced MRI time seties. Med Image Comput Comput Assist Intern Int Conf Med Image Comput Comput Assist Interv 2005 ; 8 : 91-8.
36. Lassau N, Lavisse S, Peronneau P. Evaluation précoce des traitements ciblés par DCE-US (échographie dynamique avec injection de produit de contraste). Eurocancer 2006 : 35-6.
37. Jain RK. Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Science 2005 ; 307 : 58-62.